Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.

World journal of surgical oncology - 17 Jan 2012

Wang Wen-Ping, Wang Kang-Ning, Gao Qiang, Chen Long-Qi

Abstract excerpt

BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric junction, and also to explore the possibility of treating carcinoma of esophagogastric junction using gefitinib....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Esophageal Neoplasms
Share to Gefitinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Quinazolines

Share to Stomach Neoplasms

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 22252115
DOI: 10.1186/1477-7819-10-14
PMCID: PMC3278359

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.PMID 22252115Read ↗

[Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers].Semantic proximity Read ↗

Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.Semantic proximity Read ↗

Identification of EGFR mutations in esophageal cancer.Semantic proximity Read ↗

Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines.Semantic proximity Read ↗

Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)Semantic proximity Read ↗

EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.Semantic proximity Read ↗

Absence of <i>EGFR</i> mutation in the kinase domain in common human cancers besides non‐small cell lung cancerSemantic proximity Read ↗

The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.Semantic proximity Read ↗

[Mutations in exon 19 of EGFR gene in non-small cell lung cancer from Chinese patients].Semantic proximity Read ↗

Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.Semantic proximity Read ↗

[Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer].Semantic proximity Read ↗

Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.